ArticleCell host & microbe2019
Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals.
Article in Cell host & microbe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 162 citations in OpenAlex.
- Impaired memory B-cell recall responses in the elderly following recurrent influenza vaccination.PloS one · 2021Trial
- Identifying Potential Candidate Hub Genes and Functionally Enriched Pathways in the Immune Responses to Quadrivalent Inactivated Influenza Vaccines in the Elderly Through Co-Expression Network Analysis.Frontiers in immunology · 2020Trial
- Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.Nature communications · 2019Trial
- Age-associated B cells predict coronary events in humans and aggravate murine atherosclerosis.Cardiovascular research · 2026Article
- The Influenza-Specific Immunoglobulin Repertoire - Nimble Yet Steeped in Tradition.Immunological reviews · 2026Review
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Respiratory Microbiome Remodeling in Aging: Implications for Immunosenescence and Therapeutic Intervention.Immune network · 2026Review
- Influenza vaccine-specific CD4NPJ vaccines · 2026Article
- CAPYBARA: A generalizable framework for predicting serological measurements across human cohorts.PLoS computational biology · 2026Article
- Respiratory virus immune response in the aged host.Immunity & ageing : I & A · 2026Review
- The Decline in Influenza Antibody Titers and Modifiers of Vaccine Immunity from over Ten Years of Serological Data.medRxiv : the preprint server for health sciences · 2026Article
- State-of-the-art of the high dose influenza vaccine in Spain.Frontiers in immunology · 2026Review
- Temporal single-cell analysis reveals age-associated delay in immune resolution after respiratory viral infection.bioRxiv : the preprint server for biology · 2025Article
- Characterization of two non-competing antibodies to influenza H3N2 hemagglutinin stem reveals its evolving antigenicity.Nature communications · 2025Article
- Re-evaluating CD57 as a marker of T cell senescence: implications for immune ageing and differentiation.Immunity & ageing : I & A · 2025Article
- citrOgen: a synthesis-free polysaccharide and protein antigen-presentation to antibody-induction platform.Nature communications · 2025Article
- High-throughput synthesis and specificity characterization of natively paired influenza hemagglutinin antibodies with oPoolScience translational medicine · 2025Article
- Lifelong partners: Gut microbiota-immune cell interactions from infancy to old age.Mucosal immunology · 2025Review
- Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.Vaccine · 2025Article
- Human naïve B cells show evidence of anergy and clonal redemption following vaccination.NPJ vaccines · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 8 institutions in 1 country.
Funding
Abstract
Influenza is a leading cause of death in the elderly, and the vaccine protects only a fraction of this population. A key aspect of antibody-mediated anti-influenza virus immunity is adaptation to antigenically distinct epitopes on emerging strains. We examined factors contributing to reduced influenza vaccine efficacy in the elderly and uncovered a dramatic reduction in the accumulation of de novo immunoglobulin gene somatic mutations upon vaccination. This reduction is associated with a significant decrease in the capacity of antibodies to target the viral glycoprotein, hemagglutinin (HA), and critical protective epitopes surrounding the HA receptor-binding domain. Immune escape by antigenic drift, in which viruses generate mutations in key antigenic epitopes, becomes highly exaggerated. Because of this reduced adaptability, most B cells activated in the elderly cohort target highly conserved but less potent epitopes. Given these findings, vaccines driving immunoglobulin gene somatic hypermutation should be a priority to protect elderly individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.